Voluntary announcement - phase i/ii clinical trial data of SYS6010 in combination with enlonstobart for the treatment of systemic treatment-naive, actionable genomic alteration-negative advanced nsclc orally presented at the 2026 world conference on lung cancer (wclc)
Filed with HKEX · Stock code 1093 ·
6ix hasn’t read this filing yet.
CSPC Pharmaceutical Group Limited on 6ix
Earlier from CSPC Pharmaceutical
- Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint
- Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 and Chemotherapy as Adjuvant Treatment of Breast Cancer
- Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study for Colorectal Cancer of Biparatopic HER2-targeting ADC JSKN003
- Alphamab Oncology Announces the Results of a Phase III Clinical Study of Anbenitamab (KN026) were Published in Annals of Oncology
- Alphamab Oncology Announces Biparatopic HER2-targeting ADC JSKN003 Was Granted Breakthrough Therapy Designation by the FDA for the Treatment of PROC
Later from CSPC Pharmaceutical
- Voluntary announcement - SYS6010 granted breakthrough therapy designation by nmpa in china for the treatment of patients with actionable genomic alteration-negative non-squamous non-small cell lung cancer
- Voluntary announcement - phase ii clinical trial of SYH2069 injection for the treatment of type 2 diabetes mellitus in adult patients officially initiated at the first centre in china
- 2026 Interim report
- Letter to new registered shareholders and reply form
- Notification letter to non-registered holder and request form
Follow CSPC Pharmaceutical into a list and get an email when it puts out news.
Follow CSPC Pharmaceutical